Salvage Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplant With Posttransplant Cyclophosphamide for Graft Failure in a Patient With Chronic Active Epstein-Barr Virus Infection
Experimental and Clinical Transplantation · 2023
DOI: 10.6002/ect.2022.0322 ↗Kurz gefasst
Fallbericht in der Zeitschrift Experimental and Clinical Transplantation, 2023. Verfasst von Yosuke Nakaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Graft vs Host Disease. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Salvage human leukocyte antigen-haploidentical hematopoietic cell transplant using posttransplant cyclophosphamide has shown promising results for graft failure in various hematological disorders. However, to our knowledge, no such findings have been reported for a case of chronic active Epstein-Barr virus infection, although graft failure is relatively common in patients with chronic active Epstein-Barr virus infection. We report a case of a 32-year-old woman with natural killer-cell type chronic active Epstein-Barr virus infection who experienced graft failure after a first allogeneic hematopoietic cell transplant from an unrelated human leukocyte antigen-matched donor.The patientreceived a second allogeneic hematopoietic cell transplant with human leukocyte antigen-haploidentical hematopoietic cell transplant using posttransplant cyclophosphamide (cyclophosphamide, 50 mg/kg, on day 3 and day 4) following reduced-intensity conditioning as rescue therapy. Neutrophils successfully engrafted on day 19, and the patient sustained remission without severe transplant-related complication 10 months after salvage human leukocyte antigen- haploidentical hematopoietic cell transplant using posttransplant cyclophosphamide. This report suggests that salvage human leukocyte antigen- haploidentical hematopoietic cell transplant using posttransplant cyclophosphamide may be a feasible therapeutic option for graft failure in patients with chronic active Epstein-Barr virus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Zitieren
APA
Nakaya, Y., Koh, H., Harada, N., Okamura, H., Misugi, T., Suekane, T., Tachibana, D., Kimura, H., Hino, M., & Nakamae, H. (2023). Salvage Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplant With Posttransplant Cyclophosphamide for Graft Failure in a Patient With Chronic Active Epstein-Barr Virus Infection. Experimental and Clinical Transplantation. https://doi.org/10.6002/ect.2022.0322
Vancouver
Nakaya Y, Koh H, Harada N, Okamura H, Misugi T, Suekane T, et al. Salvage Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplant With Posttransplant Cyclophosphamide for Graft Failure in a Patient With Chronic Active Epstein-Barr Virus Infection. Experimental and Clinical Transplantation. 2023. doi:10.6002/ect.2022.0322
BibTeX
@article{Nakaya2023,
author = {Nakaya, Yosuke and Koh, Hideo and Harada, Naonori and Okamura, Hiroshi and Misugi, Takuya and Suekane, Tomoki and Tachibana, Daisuke and Kimura, Hiroshi and Hino, Masayuki and Nakamae, Hirohisa},
title = {Salvage Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplant With Posttransplant Cyclophosphamide for Graft Failure in a Patient With Chronic Active Epstein-Barr Virus Infection},
journal = {Experimental and Clinical Transplantation},
year = {2023},
doi = {10.6002/ect.2022.0322}
}
EUVIMED